Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody BEC2

Known as: Anti-idiotypic Monoclonal Antibody BEC2, anti-idiotypic murine monoclonal antibody BEC2, BEC-2 
A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that is directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Idiotypic Immune Networks in Mobile-Robot Control
Jerne's idiotypic-network theory postulates that the immune response involves interantibody stimulation and suppression, as well… Expand
Highly Cited
2005
Highly Cited
2005
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of…
PURPOSE Bec2 is an anti-idiotypic antibody that mimics GD3, a ganglioside that is expressed on the surface of tumor cells and is… Expand
Review
2003
Review
2003
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.
  • P. Chapman
  • Current opinion in investigational drugs
  • 2003
    • Corpus ID: 39806825
GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an… Expand
Highly Cited
1999
Highly Cited
1999
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Despite active therapies for small cell lung cancer (SCLC), most patients relapse and die of the disease. The present study… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Highly Cited
1996
Highly Cited
1996
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
Previous attempts to immunize melanoma patients against GD3 ganglioside have been unsuccessful because of the poor immunogenicity… Expand
  • table I
  • table 2
  • figure I
  • figure 2
  • figure 3
Review
1996
Review
1996
Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases.
A new theory to explain the pathogenesis of autoimmune diseases is proposed. It is based on the idiotypic network and does not… Expand
Highly Cited
1989
Highly Cited
1989
Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.
We have previously shown that gastrointestinal cancer patients treated with monoclonal antibody CO17-1A (Ab1) developed anti… Expand
1988
1988
Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies.
Patients who undergo immunotherapy with a murine anti-colon carcinoma mAb (mAb17-1A) generate high titers of anti-idiotype and… Expand
Highly Cited
1984
Highly Cited
1984
Chronic treatment with rabbit anti-mouse mu-chain antibody alters the characteristic immunoglobulin heavy-chain restriction of murine suppressor T-cell factors.
Prolonged treatment of mice, starting at birth, with rabbit anti-mouse mu-chain antibodies resulted in the elimination of… Expand
Highly Cited
1974
Highly Cited
1974
CLONAL NATURE OF THE IMMUNE RESPONSE TO PHOSPHORYLCHOLINE
A new idiotypic determinant(s) on mouse anti-PC antibodies is described. Antibodies to the determinant(s) were raised in rabbits… Expand
  • figure 1
  • table I
  • table II
  • table III
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE